Steadybase.

SpyGlass Pharma, Inc.

Website Investor relations LinkedIn Latest 10-K
  • SGP · Nasdaq
  • Surgical & Medical Instruments & Apparatus
  • Irvine, CA
  • 65 employees
  • CIK 0001778922

Updated from SEC filings through

Top things to know

Executives

SpyGlass Pharma, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Irvine, CA. It trades as SGP on Nasdaq. It reported about 65 employees.

Five-year financials

MetricFY2025FY2024
Revenue Not on file Not on file
Operating income -$41.4M
10-K, 2026-03-26
-$27.1M
10-K, 2026-03-26
SG&A $12.3M
10-K, 2026-03-26
$7.1M
10-K, 2026-03-26
Net income -$39.9M
10-K, 2026-03-26
-$29.2M
10-K, 2026-03-26

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Jean-Frédéric Viret, Ph.D. Chief Financial Officer 10-K, March 26, 2026
James Dennewill Chief Operating Officer 10-K, March 26, 2026
Chetan Pujara, Ph.D. Chief Research and Development Officer 10-K, March 26, 2026
Ali Behbahani, M.D. Director 10-K, March 26, 2026
Habib J. Dable Director 10-K, March 26, 2026
Malik Y. Kahook, M.D. Director 10-K, March 26, 2026
Patrick Mooney Director 10-K, March 26, 2026

What SpyGlass Pharma, Inc. does

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.

Press release "About" paragraph, 10-K for the year ending October 19, 2026

Shares and governance

Shares outstanding 33.5 million (as of November 2, 2026) 10-Q, November 12, 2026
Public float $0 (as of June 30, 2025) 10-K, March 26, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 12, 2026
Auditor Deloitte & Touche LLP (Costa Mesa, CA) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 16, 2026 Capital Nexus Fund L.P. RA III
Director
Buy 1,000 $32K Form 4, November 18, 2026
November 16, 2026 Capital Management L.P. Ra
Director
Buy 1,000 $32K Form 4, November 18, 2026
November 16, 2026 Peter Kolchinsky
Director
Buy 1,000 $32K Form 4, November 18, 2026
November 16, 2026 Capital Healthcare Fund LP RA
Director
Buy 1,000 $32K Form 4, November 18, 2026
November 16, 2026 Rajeev M. Shah
Director
Buy 1,000 $32K Form 4, November 18, 2026
February 9, 2026 Bilal Arshad Khan
Director
Buy 135,000 $2.2M Form 4, February 11, 2026
February 9, 2026 Geoffrey B. Pardo
Director
Buy 312,500 $5.0M Form 4, February 11, 2026
February 9, 2026 Peter Kolchinsky
Director
Buy 3,690,000 $59.0M Form 4, February 11, 2026

Recent 8-K events

Frequently asked questions about SpyGlass Pharma, Inc.

What does SpyGlass Pharma, Inc. do?
In its own words, from Item 1 of its 10-K: "SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation."
How many employees does SpyGlass Pharma, Inc. have?
About 65 as of December 31, 2025, as stated in its annual report.
Who is the CFO of SpyGlass Pharma, Inc.?
Jean-Frédéric Viret, Ph.D., Chief Financial Officer, as named in a 10-K filed March 26, 2026.
Where is SpyGlass Pharma, Inc. headquartered?
Irvine, CA.
What is SpyGlass Pharma, Inc.'s stock ticker?
SGP on Nasdaq.
What industry is SpyGlass Pharma, Inc. in?
Surgical & Medical Instruments & Apparatus, SIC code 3841.
What is SpyGlass Pharma, Inc.'s website?
spyglasspharma.com. Investor relations: https://ir.spyglasspharma.com/.
When does SpyGlass Pharma, Inc. report earnings next?
February 4, 2027. This is an estimate from past filing dates, not a confirmed date.
Is SpyGlass Pharma, Inc. a public company?
Yes. SpyGlass Pharma, Inc. files with the SEC under CIK 0001778922 and trades as SGP.
Who audits SpyGlass Pharma, Inc.?
Deloitte & Touche LLP, Costa Mesa, CA, as named in its latest annual report (10-K).
How many shares of SpyGlass Pharma, Inc. are outstanding?
33.5 million shares as of November 2, 2026, from its 10-Q filed November 12, 2026.
What is SpyGlass Pharma, Inc.'s public float?
$0 as of June 30, 2025, as reported on the cover of its 10-K filed March 26, 2026.
How many business segments does SpyGlass Pharma, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
Have SpyGlass Pharma, Inc. insiders traded stock recently?
Since February 9, 2026, officers and directors reported 0 open-market sales and 14 purchases worth about $320M on Forms 4 and 5. The most recent: Capital Nexus Fund L.P. RA III (Director) bought 1,000 shares on November 16, 2026.